Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma

Journal of Neuro-Oncology

Volumn 128, Issue 1, 2016, Pages 147-155

  Duerinck, J ^a   Du Four, S ^a   Vandervorst, F ^a   D'Haene N ^b   Le Mercier, M ^b   Michotte, A ^a   Van Binst, A M ^a   Everaert, H ^a   Salmon, I ^b   Bouttens, F ^c   Verschaeve, V ^d   Neyns, B ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c AZ Sint Lucas Gent ^*  (Belgium)

^d GHDC   (Belgium)

Author keywords

Axitinib; Bevacizumab; Glioblastoma; Recurrent

Indexed keywords

AXITINIB; BEVACIZUMAB; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR; HEMOGLOBIN; ISOCITRATE DEHYDROGENASE 1; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; FLUORODEOXYGLUCOSE F 18; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RADIOPHARMACEUTICAL AGENT; STEROID;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; EPISTAXIS; FATIGUE; FEMALE; GLIOBLASTOMA; HOARSENESS; HUMAN; HYPERESTHESIA; HYPERSENSITIVITY; HYPERTENSION; HYPOALBUMINEMIA; HYPOTHYROIDISM; MALE; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; ORAL MUCOSITIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN INFECTION; THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT; XERODERMA; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; GENETICS; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, ALKYLATING; BEVACIZUMAB; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOBLASTOMA; HUMANS; IMIDAZOLES; INDAZOLES; LOMUSTINE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RADIOPHARMACEUTICALS; STEROIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959459146     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-016-2092-2     Document Type: Article

References (29)

1. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
2. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572–2578
3. Lamborn KR, Yung WKA, Chang SM et al (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162–170
4. Puputti M, Tynninen O, Sihto H, Blom T, Mäenpää H, Isola J, Paetau A, Joensuu H, Nupponen NN (2006) Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res 4:927–934
5. Knizetova P, Darling JL, Bartek J (2008) Vascular endothelial growth factor in astroglioma stem cell biology and response to therapy. J Cell Mol Med 12:111–125
6. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843–7848
7. Lu L, Saha D, Martuza RL, Rabkin SD, Wakimoto H (2014) Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. J Neurooncol. doi:10.1007/s11060-014-1612-1
8. Reardon DA, Turner S, Peters KB et al (2011) A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Cancer Netw 9:414–427
9. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740
10. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745
11. Batchelor TT, Mulholland P, Neyns B et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212–3218
12. Kratzsch T, Gruenwald V, Vajkoczy P, Kuhn S (2013) Use of axitinib, a new-generation tyrosine kinase inhibitor, to decrease glioblastoma growth despite primary resistance to the VEGF-antibody bevacizumab. ASCO Meet Abstr 2013(31):2077
13. Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH, Sabel M, Langen K-J (2013) Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 40:22–33
14. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28:E32
15. Widschwendter M, Siegmund KD, Müller HM, Fiegl H, Marth C, Müller-Holzner E, Jones PA, Laird PW (2004) Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64:3807–3813
16. Ogino S, Kawasaki T, Brahmandam M et al (2006) Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 8:209–217
17. D’Haene N, Le Mercier M, De Nève N et al (2015) Clinical validation of targeted next generation sequencing for colon and lung cancers. PLoS One 10:e0138245
18. Le Mercier M, D’Haene N, De Nève N, Blanchard O, Degand C, Rorive S, Salmon I (2015) Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology. Histopathology 66:215–224
19. Thorvaldsdóttir H, Robinson JT, Mesirov JP (2013) Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14:178–192
20. Hoogstraat M, Hinrichs JWJ, Besselink NJM et al (2015) Simultaneous detection of clinically relevant mutations and amplifications for routine cancer pathology. J Mol Diagn 17:10–18
21. Duerinck J, Clement PM, Bouttens F et al (2015) Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. J Neurol. doi:10.1007/s00415-014-7633-z
22. Fack F, Espedal H, Keunen O et al (2015) Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol 129:115–131
23. Götz I, Grosu AL (2013) [(18)F]FET-PET imaging for treatment and response monitoring of radiation therapy in malignant glioma patients—a review. Front Oncol 3:104
24. Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK (2015) Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 33:1197–1213
25. Zhang X, Fang X, Gao Z et al (2014) Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity. Anticancer Drugs 25:204–211
26. Stehle F, Schulz K, Fahldieck C, Kalich J, Lichtenfels R, Riemann D, Seliger B (2013) Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem 288:16334–16347
27. Bose A, Lowe DB, Rao A, Storkus WJ (2012) Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res 22:236–243
28. Du Four S, Maenhout SK, De Pierre K, Renmans D, Niclou SP, Thielemans K, Neyns B, Aerts JL (2015) Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. Oncoimmunology 4:e998107
29. Neyns B, Sadones J, Chaskis C et al (2011) Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 103:491–501